ABL Bio Inc
KOSDAQ:298380
ABL Bio Inc
Total Equity
ABL Bio Inc
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
ABL Bio Inc
KOSDAQ:298380
|
Total Equity
₩167.3B
|
CAGR 3-Years
44%
|
CAGR 5-Years
5%
|
CAGR 10-Years
N/A
|
|
|
Celltrion Inc
KRX:068270
|
Total Equity
₩17.4T
|
CAGR 3-Years
65%
|
CAGR 5-Years
44%
|
CAGR 10-Years
30%
|
|
|
SK Bioscience Co Ltd
KRX:302440
|
Total Equity
₩1.8T
|
CAGR 3-Years
4%
|
CAGR 5-Years
51%
|
CAGR 10-Years
N/A
|
|
|
H
|
Hugel Inc
KOSDAQ:145020
|
Total Equity
₩803.8B
|
CAGR 3-Years
1%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
|
P
|
PharmaResearch Co Ltd
KOSDAQ:214450
|
Total Equity
₩539.4B
|
CAGR 3-Years
21%
|
CAGR 5-Years
21%
|
CAGR 10-Years
N/A
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Total Equity
₩273.6B
|
CAGR 3-Years
26%
|
CAGR 5-Years
31%
|
CAGR 10-Years
23%
|
|
ABL Bio Inc
Glance View
ABL Bio, Inc. engages in the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. The company is headquartered in Seongnam, Gyeonggi-Do. The company went IPO on 2018-12-19. The major products include anti-angiogenesis antibodies anti-tumor targeting antibodies, T cell engager bispecific antibodies (TCEs), dual immune cell targeting bispecific antibodies (DICs), novel immune cell targeting antibodies (NICs), brain disease dual antibodies, antibody-drug conjugates (ADCs) , among others.
See Also
What is ABL Bio Inc's Total Equity?
Total Equity
167.3B
KRW
Based on the financial report for Dec 31, 2024, ABL Bio Inc's Total Equity amounts to 167.3B KRW.
What is ABL Bio Inc's Total Equity growth rate?
Total Equity CAGR 5Y
5%
Over the last year, the Total Equity growth was 126%. The average annual Total Equity growth rates for ABL Bio Inc have been 44% over the past three years , 5% over the past five years .
You don't have any saved screeners yet